Try our beta test site
88 studies found for:    myeloma and velcade | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine, Bortezomib, Prednisone
2 Recruiting Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients
Conditions: Multiple Myeloma;   High-Risk Cancer
Intervention: Drug: Bortezomib following nonmyeloablative allogeneic transplant
3 Recruiting Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Conditions: Multiple Myeloma;   Auto Stem Cell Transplant
Intervention: Drug: Bortezomib
4 Recruiting Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Condition: Multiple Myeloma
Interventions: Drug: Melphalan;   Drug: Bortezomib
5 Not yet recruiting Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Vorinostat Velcade Dexamethasone
6 Recruiting Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Dexamethasone
7 Recruiting Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
8 Recruiting Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Drug: Prednisone
9 Recruiting Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
10 Recruiting Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Granulocyte colony-stimulating factor (G-CSF);   Drug: Mozobil
11 Recruiting A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
12 Recruiting Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Bortezomib;   Drug: Dexamethasone
13 Recruiting Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Plitidepsin;   Drug: Bortezomib;   Drug: Dexamethasone
14 Recruiting A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Velcade;   Drug: Melphalan;   Drug: Prednisone;   Drug: Daratumumab;   Drug: Dexamethasone
15 Recruiting Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab;   Drug: Bortezomib;   Drug: Dexamethasone
16 Recruiting Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
Condition: Multiple Myeloma (MM)
Interventions: Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Lenalidomide
17 Recruiting Modified Bortezomib-based Combination Therapy for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Mitoxsnteone;   Drug: Thalidomide
18 Recruiting Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib-Melphalan;   Drug: Melphalan
19 Recruiting Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: total marrow irradiation;   Drug: tacrolimus;   Drug: sirolimus;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
20 Recruiting A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
Condition: Multiple Myeloma
Interventions: Drug: Revlimid;   Drug: Velcade;   Drug: dexamethasone;   Drug: Farydak

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.